Nxera Pharma Notes Successful Development Progress Of Partnered Schizophrenia Candidate Nbi-1117568
16/04/2024 07:35
April 16 (Reuters) - Nxera Pharma Co Ltd 4565.T :
* NXERA PHARMA CO LTD: NXERA PHARMA NOTES SUCCESSFUL
DEVELOPMENT
PROGRESS OF PARTNERED SCHIZOPHRENIA CANDIDATE NBI-1117568
* NXERA PHARMA CO LTD: ACHIEVEMENT OF THIS IMPORTANT SAFETY
DEVELOPMENT MILESTONE TRIGGERS A $15 MLN PAYMENT TO NXERA FROM
NEUROCRINE
Source text for Eikon: ID:nTSpp8b8e0
Further company coverage: 4565.T NBIX.O
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up